Literature DB >> 18453343

The National Emphysema Treatment Trial (NETT): a study in agency collaboration.

Gail G Weinmann1, Yen-Pin Chiang, Steven Sheingold.   

Abstract

The National Emphysema Treatment Trial (NETT) was a multicenter, randomized, controlled clinical trial, comparing the efficacy of lung volume reduction surgery (LVRS) plus medical management with rehabilitation to medical management with rehabilitation in 1,218 patients with severe emphysema. The NETT was a precedent-setting collaborative effort of three government agencies: the Centers for Medicare and Medicaid Services (CMS); the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH); and the Agency for Healthcare Research and Quality (AHRQ). NETT provided Medicare beneficiaries with controlled access to a promising but unproven procedure, while scientifically valid data on the efficacy and costs were collected to guide future use, coverage decisions, and policy. NETT demonstrates that collaboration among federal agencies and among health plans, researchers, and providers can successfully fulfill their differing missions simultaneously and is a productive approach to evaluating new treatments of mutual interest.

Entities:  

Mesh:

Year:  2008        PMID: 18453343      PMCID: PMC2645307          DOI: 10.1513/pats.200709-154ET

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  6 in total

1.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Authors:  Sean R Tunis; Steven D Pearson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

2.  Evaluation and research in lung volume reduction surgery.

Authors:  G G Weinmann; R Hyatt
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

3.  Patients at high risk of death after lung-volume-reduction surgery.

Authors:  Alfred Fishman; Henry Fessler; Fernando Martinez; Robert J McKenna; Keith Naunheim; Steven Piantadosi; Gail Weinmann; Robert Wise
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

4.  Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease.

Authors:  J D Cooper; E P Trulock; A N Triantafillou; G A Patterson; M S Pohl; P A Deloney; R S Sundaresan; C L Roper
Journal:  J Thorac Cardiovasc Surg       Date:  1995-01       Impact factor: 5.209

5.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.

Authors:  Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood
Journal:  N Engl J Med       Date:  2003-05-20       Impact factor: 91.245

6.  Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema.

Authors:  Scott D Ramsey; Kristin Berry; Ruth Etzioni; Robert M Kaplan; Sean D Sullivan; Douglas E Wood
Journal:  N Engl J Med       Date:  2003-05-20       Impact factor: 91.245

  6 in total
  6 in total

1.  Subgroup analysis of symptoms and their effect on functioning, exercise capacity, and physical activity in patients with severe chronic obstructive pulmonary disease.

Authors:  Soo Kyung Park; Catherine A Meldrum; Janet L Larson
Journal:  Heart Lung       Date:  2013-09-20       Impact factor: 2.210

Review 2.  The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery.

Authors:  Gerard J Criner; Francis Cordova; Alice L Sternberg; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

3.  Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access.

Authors:  Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Health Aff (Millwood)       Date:  2022-03       Impact factor: 6.301

Review 4.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.

Authors:  Chinedu O Ejike; Han Woo; Panagis Galiatsatos; Laura M Paulin; Jerry A Krishnan; Christopher B Cooper; David J Couper; Richard E Kanner; Russell P Bowler; Eric A Hoffman; Alejandro P Comellas; Gerard J Criner; R Graham Barr; Fernando J Martinez; MeiLan K Han; Carlos H Martinez; Victor E Ortega; Trisha M Parekh; Stephanie A Christenson; Neeta Thakur; Aaron Baugh; Daniel C Belz; Sarath Raju; Amanda J Gassett; Joel D Kaufman; Nirupama Putcha; Nadia N Hansel
Journal:  Am J Respir Crit Care Med       Date:  2021-04-15       Impact factor: 30.528

6.  Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts.

Authors:  Matthew Moll; Phuwanat Sakornsakolpat; Nick Shrine; Brian D Hobbs; Dawn L DeMeo; Catherine John; Anna L Guyatt; Michael J McGeachie; Sina A Gharib; Ma'en Obeidat; Lies Lahousse; Sara R A Wijnant; Guy Brusselle; Deborah A Meyers; Eugene R Bleecker; Xingnan Li; Ruth Tal-Singer; Ani Manichaikul; Stephen S Rich; Sungho Won; Woo Jin Kim; Ah Ra Do; George R Washko; R Graham Barr; Bruce M Psaty; Traci M Bartz; Nadia N Hansel; Kathleen Barnes; John E Hokanson; James D Crapo; David Lynch; Per Bakke; Amund Gulsvik; Ian P Hall; Louise Wain; Scott T Weiss; Edwin K Silverman; Frank Dudbridge; Martin D Tobin; Michael H Cho
Journal:  Lancet Respir Med       Date:  2020-07       Impact factor: 102.642

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.